Reduction of door-to-balloon time by new performance processes in patients with ST-segment elevation myocardial

Young Hee Nam1, Kwang Soo Cha, Jeong Hwan Kim

  • 1Department of Cardiology, Dong-A University Hospital, Busan, South Korea.

Angiology
|September 1, 2010
PubMed

Insights

Implementing new performance processes significantly reduced door-to-balloon time for primary percutaneous coronary intervention (PCI). This improvement enhances patient care by speeding up critical treatment delivery.

Area of Science:

  • Cardiology
  • Healthcare Management
  • Quality Improvement

Background:

  • Door-to-balloon time is a critical metric in primary percutaneous coronary intervention (PCI).
  • Delays in PCI can lead to adverse cardiac outcomes.
  • Optimizing workflow processes is essential for improving patient care.

Purpose of the Study:

  • To evaluate the impact of adopting new performance processes on door-to-balloon time for primary PCI.
  • To assess the effectiveness of specific workflow changes in reducing treatment delays.

Main Methods:

  • A pre- and post-implementation study design was used.
  • Three new performance processes were introduced: concurrent emergency department activation, direct phone calls for activation, and patient transfer before PCI team arrival.
  • 139 consecutive patients undergoing primary PCI were analyzed.

Main Results:

  • Median door-to-balloon time significantly decreased from 133 to 76 minutes (P < .0001).
  • The percentage of patients treated within 90 minutes increased from 16% to 72% (P < .0001).
  • Significant reductions were observed in door-to-consent time and door-to-laboratory arrival time.

Conclusions:

  • The adoption of new performance processes led to a substantial reduction in door-to-balloon time for primary PCI.
  • These workflow improvements significantly increased the proportion of patients receiving timely treatment.
  • Optimized processes are effective in accelerating critical cardiac intervention delivery.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...